此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

接受血管内治疗的急性缺血性卒中患者的血清电解质与对比剂肾病

血清电解质水平对接受血管内治疗的急性缺血性脑卒中患者对比剂肾病风险的影响

This study aims to evaluate the relationship between serum electrolyte levels and the development of contrast-induced acute kidney injury (CI-AKI) in patients with acute ischemic stroke undergoing endovascular therapy (EVT).

Contrast-induced nephropathy remains a significant complication associated with endovascular procedures and is linked to increased morbidity and mortality. While several risk factors have been identified, the role of serum electrolyte imbalances in the development of CI-AKI has not been fully elucidated.

In this retrospective cohort study, patients treated with EVT between 2018 and 2026 will be analyzed. Patients will be classified based on the presence or absence of CI-AKI according to changes in serum creatinine levels. Demographic data, comorbidities, laboratory parameters-including serum electrolytes-and procedural variables will be compared between groups.

The primary objective is to determine whether serum electrolyte levels are associated with the risk of CI-AKI. Secondary objectives include evaluating 90-day mortality and dialysis dependency in patients who develop CI-AKI.

研究概览

详细说明

This retrospective cohort study is designed to evaluate the association between serum electrolyte levels and the development of contrast-induced acute kidney injury (CI-AKI) in patients undergoing endovascular therapy (EVT) for acute ischemic stroke.

Endovascular treatment has become a standard of care for acute ischemic stroke; however, the use of iodinated contrast media carries a risk of nephrotoxicity. Contrast-induced acute kidney injury remains a clinically significant complication and is associated with prolonged hospitalization, increased healthcare costs, and higher mortality rates. Although several well-established risk factors for CI-AKI have been identified, including baseline renal dysfunction, diabetes mellitus, and contrast volume, the role of serum electrolyte imbalances has not been clearly defined.

Electrolyte disturbances may influence renal perfusion, tubular function, and systemic hemodynamics, potentially contributing to the pathophysiology of CI-AKI. Therefore, identifying electrolyte-related risk factors may help improve risk stratification and guide preventive strategies in high-risk populations.

In this study, patients who underwent EVT between 2018 and 2026 will be included. Prospectively collected clinical data will be analyzed retrospectively. Patients will be divided into two groups based on the development of CI-AKI, defined according to changes in serum creatinine levels following contrast exposure.

Comparative analyses will be performed between patients with and without CI-AKI to identify potential predictors. Multivariate regression analysis may be used to determine independent risk factors associated with CI-AKI development.

The findings of this study are expected to provide clinically relevant insights into the role of electrolyte balance in the development of CI-AKI and may contribute to improved peri-procedural risk assessment and patient management strategies in acute ischemic stroke populations undergoing endovascular therapy.

研究类型

观察性的

注册 (实际的)

4760

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Outside of the US
      • Diyarbakır、Outside of the US、土耳其(türkiye)、21070
        • Fatma Acil

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 100年 (成人、年长者)

接受健康志愿者

不适用

有资格学习的性别

全部

取样方法

非概率样本

研究人群

This study includes adult patients (≥18 years) with acute ischemic stroke who underwent endovascular therapy at a tertiary referral center between 2018 and 2026. Patients with sufficient clinical and laboratory data, including pre- and post-procedural serum creatinine measurements, will be eligible for inclusion.

The cohort reflects a real-world population of patients undergoing EVT, encompassing a wide range of demographic and clinical characteristics, including common vascular comorbidities. Patients will be stratified according to the development of contrast-induced acute kidney injury (CI-AKI) for comparative analyses.

描述

Inclusion Criteria:

  • Adults aged 18 years or older
  • Patients diagnosed with acute ischemic stroke
  • Patients who underwent endovascular therapy for acute ischemic stroke between 2018 and 2026
  • Patients with a baseline NIHSS score of 6 or higher
  • Patients who received iodinated contrast medium during the endovascular procedure
  • Patients managed under general anesthesia
  • Patients with available pre-procedural and post-procedural serum creatinine measurements sufficient to assess contrast-induced acute kidney injury

Exclusion Criteria:

  • Age younger than 18 years
  • Pre-existing acute kidney injury or chronic kidney disease meeting KDIGO stage 1-3 before endovascular therapy
  • APACHE score greater than 25 at the time of the procedure
  • Known allergy or hypersensitivity to iodinated contrast media
  • Exposure to iodinated contrast media within the previous 2 weeks
  • Use of nephrotoxic medications within the previous 2 weeks
  • History of myocardial infarction or previous stroke
  • Use of vasopressor/inotropic agents such as dopamine at the time of the procedure
  • Systemic steroid use at the time of the procedure
  • Incomplete medical records or missing laboratory data required for evaluation of CI-AKI

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:RETROSPECTIVE

队列和干预

团体/队列
干预/治疗
CI-AKI Group

Patients who developed contrast-induced acute kidney injury (CI-AKI) following endovascular therapy for acute ischemic stroke, defined by an increase in serum creatinine levels according to established diagnostic criteria after contrast exposure. These patients were identified based on post-procedural renal function changes and included in the analysis to evaluate clinical, laboratory, and procedural factors associated with CI-AKI development.

No experimental or therapeutic intervention was assigned. This observational retrospective cohort study evaluated patients undergoing endovascular therapy for acute ischemic stroke, who were subsequently categorized based on the presence or absence of contrast-induced acute kidney injury (CI-AKI). The study analyzed demographic, clinical, laboratory (including serum electrolyte levels) and procedural variables to identify potential risk factors associated with CI-AKI development.

Non-CI-AKI Group

Patients who underwent endovascular therapy for acute ischemic stroke but did not develop contrast-induced acute kidney injury based on post-procedural serum creatinine measurements.

No experimental or therapeutic intervention was assigned. This observational retrospective cohort study evaluated patients undergoing endovascular therapy for acute ischemic stroke, who were subsequently categorized based on the presence or absence of contrast-induced acute kidney injury (CI-AKI). The study analyzed demographic, clinical, laboratory (including serum electrolyte levels) and procedural variables to identify potential risk factors associated with CI-AKI development.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Incidence of contrast-induced acute kidney injury (CI-AKI)
大体时间:Within 48-72 hours after contrast exposure

CI-AKI will be identified based on post-procedural serum creatinine changes after contrast exposure according to established diagnostic criteria.

Within 48-72 hours after contrast exposure

次要结果测量

结果测量
措施说明
大体时间
90-day mortality
大体时间:Within 90 days after endovascular therapy

All-cause mortality occurring within 90 days after endovascular therapy in patients with and without contrast-induced acute kidney injury (CI-AKI).

Within 90 days after endovascular therapy
Dialysis dependency in patients with CI-AKI
大体时间:Within 90 days after endovascular therapy

Requirement for renal replacement therapy (hemodialysis) within 90 days after endovascular therapy in patients who developed contrast-induced acute kidney injury (CI-AKI)

Within 90 days after endovascular therapy
Change in serum creatinine
大体时间:Baseline to 48-72 hours after endovascular therapy

Change in serum creatinine levels from baseline to post-procedural measurements following contrast exposure.

Baseline to 48-72 hours after endovascular therapy
Association between serum electrolyte levels and CI-AKI
大体时间:Baseline (pre-procedural measurements)

Evaluation of the relationship between baseline serum electrolyte levels (sodium, potassium, chloride, calcium, magnesium, phosphate) and the development of contrast-induced acute kidney injury.

Baseline (pre-procedural measurements)
Length of hospital stay
大体时间:Within 90 days after endovascular therapy

Total duration of hospitalization in days, compared between patients with and without CI-AKI.

Within 90 days after endovascular therapy
Inflammatory markers and CI-AKI relationship
大体时间:Baseline (pre-procedural measurements)

Association between inflammatory markers (e.g., C-reactive protein, procalcitonin) and the development of CI-AKI.

Baseline (pre-procedural measurements)
Change in estimated glomerular filtration rate (eGFR)
大体时间:Baseline to 48-72 hours after endovascular therapy

Change in estimated glomerular filtration rate (eGFR) from baseline to post-procedural measurements following contrast exposure

Baseline to 48-72 hours after endovascular therapy

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年4月23日

初级完成 (实际的)

2026年11月10日

研究完成 (实际的)

2026年11月11日

研究注册日期

首次提交

2026年4月2日

首先提交符合 QC 标准的

2026年4月16日

首次发布 (实际的)

2026年4月22日

研究记录更新

最后更新发布 (实际的)

2026年11月18日

上次提交的符合 QC 标准的更新

2026年11月13日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅